Trial ID or NCT#

NCT00703820

Status

RECRUITING

Purpose

The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy—haploidentical NK cell transplantation—in patients with standard-risk AML. In addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly diagnosed patients with AML and attempt to optimize outcome through the use of MRD-adapted therapy and further improvements in supportive care.

Official Title

AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia

Eligibility Criteria

Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Gary Dahl
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology) at the Lucile Salter Packard Children's Hospital

Contact us to find out if this trial is right for you.

CONTACT

Christina Baggott
(650) 497-7659